Today: 29 June 2026
IREN stock slides into the weekend — here’s what matters before Monday’s open
22 February 2026
1 min read

IREN stock slides into the weekend — here’s what matters before Monday’s open

New York, Feb 22, 2026, 14:32 EST — The market finished the day closed.

  • IREN dropped 7.6% to close Friday at $39.98, with shares moving between $39.53 and $44.25 during the session.
  • The stock slipped, but losses were milder than those seen by a handful of other U.S.-listed bitcoin miners.
  • Feb. 27 is circled on traders’ calendars, with the MSCI index inclusion seen as the next key catalyst.

IREN Limited shares slid 7.6% on Friday, closing at $39.98. The stock bounced from $39.53 up to $44.25 during the session, with roughly 41.9 million shares changing hands.

Bitcoin shed roughly 1.7% during the session. Several public miners also closed down, though losses stayed narrower. Shares of Riot Platforms slid 3.4%, Core Scientific dropped 3.6%, and CleanSpark gave up 1.7%. Marathon Digital ended the day mostly flat.

Why it matters now: IREN tends to swing sharply among crypto miners, and there’s a big date coming up. The company is set to join the MSCI USA Index right after markets close on Feb. 27, according to its announcement.

Daniel Roberts, co-founder and co-CEO of IREN, described the index move as evidence of the company’s “scale and liquidity.” IREN, for its part, said the inclusion could raise its profile with institutional and index-focused investors. GlobeNewswire

The tape’s in charge for the moment. Friday’s drop leaves investors eyeing IREN for signs of stability when U.S. trading resumes Monday. Focus also stays on whether crypto-linked stocks continue trading in lockstep, or if the group splits apart.

The stock has spent much of this month reacting to its latest earnings release. For the quarter ended Dec. 31, IREN posted $184.7 million in total revenue—$167.4 million from bitcoin mining, $17.3 million from AI cloud services—while recording a net loss of $155.4 million. “Strongest demand environment to date,” said Roberts. The company stuck to its target of reaching $3.4 billion in annual recurring revenue (ARR) by the end of 2026, a figure that annualizes current revenue but remains partially based on assumptions, not firm contracts. GlobeNewswire

The risk is clear enough: if bitcoin slides, cash from mining dries up fast, and the stock usually exaggerates the drop. On another front, slower rollouts of graphics chips or sluggish AI customer signups could unsettle expectations tied to the company’s new direction.

Investors are tracking more than just daily crypto swings—they’re eyeing mechanical buying tied to the MSCI inclusion date, watching to see if that appetite sticks after the event wraps up.

Zacks’ earnings calendar puts the next earnings report on May 13.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • UK's Scancell proposes reverse merger with Nasdaq-listed Neuphoria to boost US investor presence
    June 29, 2026, 10:20 AM EDT. UK-based biotech Scancell Holdings has proposed a reverse merger with Neuphoria Therapeutics, listed on Nasdaq, to secure a U.S. listing and enhance its profile among American specialist investors. The all-stock deal details remain undisclosed. Neuphoria's shares have steeply declined after its lead drug soclenicant failed a late-stage social anxiety trial, prompting a strategic review and suitor interest, including offers from hedge fund Lynx1 Master Fund. Neuphoria maintains a partnership with Merck, with potential milestone revenues of up to $450 million. Meanwhile, Scancell aims to advance its own melanoma and cancer vaccine candidates, seeking equity and debt financing for its phase 3 studies. The deal appears driven more by Scancell's desire for Nasdaq access than Neuphoria's pipeline assets.
Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Previous Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod
Next Story

Eli Lilly stock pops after Novo trial miss, new Zepbound pen gets FDA nod

Go toTop